Cargo-encapsulated cells for drug delivery  

作　　者：Zhaowei Chen Di Wen Zhen Gu 

机构地区：[1]MOE Key Laboratory for Analytical Science of Food Safety and Biology,College of Chemistry,Fuzhou University,Fuzhou 350108,China [2]Department of Bioengineering,University of California,Los Angeles,CA 90095,USA [3]California NanoSystems Institute,University of California,Los Angeles,CA 90095,USA [4]Jonsson Comprehensive Cancer Center,University of California,Los Angeles,CA 90095,USA [5]Center for Minimally Invasive Therapeutics,University of California,Los Angeles,CA 90095,USA

出　　处：《Science China(Life Sciences)》2020年第4期599-601,共3页中国科学（生命科学英文版）

基　　金：This work was supported by grants from the start-up package of University of California,Los Angeles,USA.

摘　　要：Synthetic micro-/nanoparticle(MNP)carriers,either organic or inorganic ones,have advanced considerably in recent years for drug delivery with the aim of enhancing drug solubility/stability,reducing systemic toxicity and increasing dosing at pathological sites(Chen and Liang,2018;Xiang et al.,2018).Specially,the properties of MNPs,such as size,morphology,or surface groups,can be easily modulated to maximize their potency in delivering drugs to the targeted areas(Ran and Xue,2018).Nevertheless,till now,only a handful of MNPs have been approved by the US Food and Drug Administration for clinical application.Although numerous proof-of-concept studies of MNPs in animal models are in progress or are being clinically evaluated,synthetic MNPs are still struggling to reach the clinical expectations.

关 键 词：PROOF SOLUBILITY INORGANIC 

分 类 号：R943[医药卫生—药剂学]